Company timeline
알테오젠
Aug. 5, 2026 — Oct. 6, 2026 · 4 stories
DART corporate ID 00989619
Filing dates come from the original receipt records. Story dates show when we reported them. The sequence groups our coverage of one company; it does not imply causes or outcomes.
Follow the filing dates
· Filed
Korean filing: 투자판단관련주요경영사항 (재조합 인간 히알루로니다제 제품 ALTB4 독점적 라이선스 계약 체결)
Alteogen signs ALT-B4 license with undisclosed pharmaceutical company
The agreement grants an undisclosed global pharmaceutical company exclusive development and commercialization rights for a subcutaneous formulation of one biopharmaceutical product using ALT-B4.
Our story
· Filed
Korean filing: 연결재무제표기준영업(잠정)실적(공정공시)
Alteogen posts second-quarter profit as commercial sales take hold
Alteogen reported second-quarter net income after a year-earlier loss as sales of partner products began generating commercial revenue.
Our story
· Filed
Korean filing: 주요사항보고서(회사합병결정)
Alteogen to absorb biolabs unit in small-scale merger
Alteogen will absorb its 62.9-percent-owned subsidiary Alteogen BioLogics to bring its pipeline and sales operations in-house, issuing 600,477 new shares with a merger date set for Dec. 29.
Our story
· Filed
Korean filing: 회사합병결정(종속회사의주요경영사항)
Alteogen to absorb biologics unit in all-stock merger
Alteogen will absorb its 62.9 percent-owned affiliate Alteogen Biologics in a small-scale merger aimed at consolidating development and commercialization under one roof.
Our story
Our filing-based coverage over the past 180 days. This is not a complete list of disclosures or events; an announced contract or plan does not mean it has been completed.